Rozita Khodashahi

Dr. Rozita Khodashahi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2020 in Infectious Diseases
Verified
Journal Article
Closed access
RKRozita Khodashahi
Rozita Khodashahi
SSSoroush Sarjamee
Soroush Sarjamee
Septic shock is the main cause of morbidity and mortality in patients and second leading cause of mortality among subjects in noncoronary intensive care units. Based on the literature, elevated serum lactate levels are associated with poor outcomes in patients with septic shock, which may occur due to various reasons, such as tissue hypoxia and anaerobic metabolism. This systematic review was conducted to collect data on the lactate area and area under the curve (AUC) of serial lactate levels for the determination of the predictive values of these factors to diagnose septic shock. For this purpose, the articles published up to 2019 were searched in four databases, including Google Scholar, PubMed, Scopus, and Medline. This study was carried out based on the seven stages recommended in the Cochrane Handbook. All articles were searched using several keywords, including ‘Lactate Area Score’ and ‘Serial Lactate Levels’ in combination with ‘Septic Shock’. There were a total of 14 studies mainly focused on the assessment of the lactate area and serial lactate levels in patients with septic shock. The inclusion criteria were a clear explanation of the predictive role of repeated lactate measurements in patients with septic shock, sample size larger than 50, examination on human samples, and publication in English. All case-control, prospective, and retrospective studies on human subjects assessing the predictive value of repeated lactate measurements in the diagnosis of patients with septic shock at high risk of mortality were entered in the present review. The lactate area is a new concept introduced as the sum of the AUC of serial lactate levels. This factor can determine the severity and duration of hyperlactatemia. Based on the obtained results, there was an association between the lactate area score and 28-day mortality of patients with septic shock; therefore, early lactate area score can be considered a prognostic marker for the prediction of mortality rate in these patients. There are few studies on the evaluation of the lactate area score and no more information about the prognostic ability of the lactate area score. This was the main limitation of the present study. Moreover, the lactate area is introduced as the sum of the AUC of serial lactate levels and cannot reflect the trend of serial lactate. The trend may be supported by lactate clearance but not lactate area.

12 May 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
HBHossein Bahari
Hossein Bahari
MJMostafa Shahraki Jazinaki
Mostafa Shahraki Jazinaki
MAMohsen Aliakbarian
Mohsen Aliakbarian
MRMohammad Rashidmayvan
Mohammad Rashidmayvan
HGHaniyeh Golafrouz
Haniyeh Golafrouz
MMMahsa Malekahmadi
Mahsa Malekahmadi
Background: Although a large number of trials have observed the anti-inflammatory properties of propolis, the currently available research remains controversial regarding its beneficial health effects. Hence, the purpose of this study was to examine the effect of propolis on inflammatory and oxidative stress markers in adults.Methods: A comprehensive search was performed in Scopus, Web of Science, and PubMed/Medline to find relevant randomized controlled trials (RCTs) until January 2024. The overall effect sizes were calculated using the random-effects model and expressed as weighted mean differences (WMD) with a 95% confidence interval (CI). The possible heterogeneity between included trials was assessed by performing Cochran’s Q test.Results: In total, 27 trials with 29 treatment arms were eligible for inclusion in this review. This meta-analysis revealed that propolis consumption led to a significant decrease in C-reactive protein (CRP) (WMD: –1.23; 95%CI: –1.76, –0.69; p < 0.001), Interleukin-6 (IL-6) (WMD: –1.52; 95%CI: –2.10, –0.93; p < 0.001), Tumor necrosis factor-α (WMD: –1.15; 95%CI: –1.75, –0.55; p < 0.001), and Monocyte chemoattractant protein-1 (MCP-1) (WMD: –35.33; 95%CI: –50.28, –20.37; p < 0.001), and a significant increase in total antioxidant capacity (TAC) (WMD: 0.32; 95%CI: 0.12, 0.51; p = 0.001), Glutathione (GSH) (WMD: 4.71; 95%CI: 3.17, 6.25; p < 0.001), and Glutathione peroxidase (GPx) (WMD: 44.75; 95%CI: 5.10, 84.40; p = 0.02). However, there were no significant effects on IL-10, IL-2, IL-8, pro-oxidant-antioxidant balance (PAB), malondialdehyde (MDA), and superoxide dismutase (SOD) in comparison to the control group.Conclusion: Propolis supplementation appears effective in reducing inflammation and oxidative stress by enhancing antioxidant capacity and reducing specific inflammatory markers. However, variations in study designs, dosages, and participant characteristics contribute to the heterogeneity of results. Further well-designed RCTs are needed to confirm these findings and determine the optimal dosage and long-term effects. Given its potential anti-inflammatory and antioxidant properties, propolis may serve as a complementary approach in managing inflammation-related conditions, though its clinical application requires further validation.Systematic review registration: https://clinicaltrials.gov/, identifier CRD42023474033.

13 March 2021 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RKRozita Khodashahi
Rozita Khodashahi
HNHamid Reza Naderi
Hamid Reza Naderi
ASAlireza Sedaghat
Alireza Sedaghat
AAAbolghasem Allahyari
Abolghasem Allahyari
SSSoroush Sarjamee
Soroush Sarjamee
MKMandana Khodashahi
Mandana Khodashahi
Background: It seems that the risk of developing complications associated with coronavirus disease 2019 (COVID-19) is higher among individuals with weakened immune systems. Objectives: Therefore, this study was carried out to determine the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of patients not entering the intubation phase compared to those entering the intubation phase. Methods: This descriptive case-control study was performed on 26 patients with COVID-19 referring to Imam Reza hospital in Mashhad, Iran, in March 2020. For subjects with COVID-19 not responding to the standard three-drug protocol (i.e., ribavirin, hydroxychloroquine, and lopinavir/ritonavir), three doses of IVIG (0.4 g/kg/day) were added to the protocol. The patients were divided into two groups of subjects not entering the intubation phase and those entering the intubation phase and compared in terms of different variables. Results: The comparison of laboratory findings showed a significant difference before and after receiving IVIG regarding oxygen saturation (P < 0.005), white blood cell (P = 0.001), hemoglobin level (P = 0.0002), lymphocyte count (P = 0.03), and C-reactive protein (P = 0.001). In general, 53.8% and 46.2% of the patients were discharged and expired, respectively. All the subjects not entering the intubation phase were recovered; nevertheless, only one case entering the intubation phase was recovered, and 92.3% of the patients expired. A significant difference was observed between the patients not entering the intubation phase and those entering the intubation phase in terms of mortality (χ2 = 22.28; P < 0.005). Conclusions: In summary, the obtained results of the current study confirmed the therapeutic effects of IVIG on patients with COVID-19. Moreover, better treatment results, shorter hospital stay, and lower mortality rates were observed among COVID-19 patients who did not enter the intubation phase in comparison with those entering the intubation phase.

1 January 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
RAReza Nejad Shahrokh Abadi
Reza Nejad Shahrokh Abadi
MJMostafa Shahraki Jazinaki
Mostafa Shahraki Jazinaki
HBHossein Bahari
Hossein Bahari
MRMohammad Rashidmayvan
Mohammad Rashidmayvan
MAMohammad Reza Amini
Mohammad Reza Amini
MMMahsa Malekahmadi
Mahsa Malekahmadi
Background: Several previous studies indicated that melatonin supplementation may positively affect glycemic control in patients with diabetes. However, research on the influence of melatonin supplementation on glycemic parameters remains inconclusive. Therefore, this study aimed to assess the impacts of melatonin supplementation on glycemic parameters in type 2 diabetes by conducting a meta-analysis. Methods: PubMed/Medline, Scopus, and Web of Science were comprehensively searched until July 2024 to find eligible randomized clinical trials (RCTs). The overall effect sizes were estimated by using the randomeffect model and presented as weighted mean differences (WMD) with a 95% confidence interval (CI). Furthermore, the heterogeneity among the included trials was assessed by performing the Cochran Q test and interpreted based on the I² statistic. Results: Of the 1361 papers, eight eligible RCTs were included in this meta-analysis. Our findings indicated that melatonin supplementation significantly decreased fasting blood glucose (WMD = -12.65 mg/dl; 95% CI: -20.38, -4.92; P = 0.001), insulin (WMD = -2.30 μU/ml; 95% CI: -3.20, -1.40; P < 0.001), hemoglobin A1c (WMD = -0.79 %; 95% CI: -1.28, -0.29; P = 0.002), and HOMA-IR (WMD, -0.83; 95% CI: -1.59 to - 0.07; P = 0.03). Conclusion: According to the results of the current meta-analysis, persons with type 2 diabetes who supplement with melatonin had improved glycemic control. It looks that supplementing with melatonin at a dose exceeding 6 mg daily for over a period of 12 weeks may be more successful than other forms of intervention. Nevertheless, further research with larger sample sizes is necessary to draw definitive conclusions.

13 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
HHHamed Hosseini
Hamed Hosseini
ASAnahita Sadeghi
Anahita Sadeghi
PTPayam Tabarsi
Payam Tabarsi
AEAzin Etemadimanesh
Azin Etemadimanesh
IDIlad Alavi Darazam
Ilad Alavi Darazam
MSMohammadreza Salehi
Mohammadreza Salehi
Introduction: After emerging the global pandemic of SARS-CoV2 some preliminary studies demonstrated the efficacy of antiviral treatments. But shortly thereafter, inconsistencies in the results of further clinical trials raised doubts on the efficacy of these agents. In this study, we aimed to evaluate the effect of Remdesivir on hospitalized COVID-19 patients’ outcomes. Material and methods: This study was an open-label, single-armed, clinical trial on hospitalized patients diagnosed with COVID-19 who had progressive respiratory symptoms despite receiving standard care. All patients received Remdesivir and their characteristics, outcomes, time of treatment initiation, and respiratory support stages during hospitalization were registered and followed up for 14 days. Results: 145 patients with the mean age of 52.89 ± 1.12 years enrolled in this study, 38 (26.2%) died at the end of 14 days period. The mean time interval from the onset of the symptoms to antiviral treatment was 10.63±0.56 days. Thirty deceased patients (78.9%) were men, showing 2.8 times higher mortality chance compared to women (OR adj =2.77; 95%CI=1.08-7.09). The type of respiratory support on the first day of treatment initiation showed a significantly lower mortality chance in patients receiving O 2 only than those who needed non-invasive and/or mechanical ventilation (OR adj =3.91; 95%CI=1.64-9.32). The start time (early vs late administration) and duration (less or more than 7 days) of antiviral treatment had no statistically significant association with mortality or ventilation escalation among the patients (p-value > 0.05). Conclusion: In this study, we showed that Remdesivir probably is not effective on the outcome of hospitalized COVID-19 patients.

18 July 2020 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RKRozita Khodashahi
Rozita Khodashahi
ASAlireza Sedaghat
Alireza Sedaghat
MKMandana Khodashahi
Mandana Khodashahi
Introduction: The outbreak of coronavirus disease 2019 (COVID-19) should be considered a serious threat to global public health. Due to a large number of infected and dead people, the development of approaches to control the epidemic condition, as well as effective and available drugs, is very important. Case Presentation: In this study, we presented three cases with COVID-19 admitted to the Imam Reza Hospital. A high dose of intravenous immunoglobulin (IVIG) was used for patients as potent and safe treatment. Moreover, case reports and case series focusing on the patients with COVID-19 were reviewed in the present study. During the literature search, 27 patients with COVID-19 were identified in 14 studies. Fever, sore throat, dry cough, fatigue, chills, and muscle pain were the common primary complications of the patients. Kaletra, oseltamivir, ceftriaxone, hydroxychloroquine, azithromycin, and IVIG were the most prevalent drugs for the treatment of COVID-19. Conclusions: Except for the current study, IVIG was utilized in two other studies to treat patients with COVID-19, who did not respond to other therapies.